Novozymes A/S (OTCMKTS:NVZMY – Get Free Report) reached a new 52-week low on Tuesday . The stock traded as low as $53.92 and last traded at $54.66, with a volume of 33976 shares. The stock had previously closed at $55.46.
Novozymes A/S Stock Performance
The firm has a market cap of $22.60 billion, a price-to-earnings ratio of 38.94, a P/E/G ratio of 1.03 and a beta of 1.11. The firm’s 50 day moving average price is $61.88 and its 200-day moving average price is $62.24. The company has a debt-to-equity ratio of 0.26, a current ratio of 1.61 and a quick ratio of 1.00.
Novozymes A/S (OTCMKTS:NVZMY – Get Free Report) last released its quarterly earnings data on Wednesday, February 25th. The biotechnology company reported $0.35 earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $0.79 by ($0.44). Novozymes A/S had a net margin of 13.96% and a return on equity of 6.38%. The firm had revenue of $1.18 billion for the quarter, compared to the consensus estimate of $1.22 billion. On average, analysts anticipate that Novozymes A/S will post 1.82 earnings per share for the current year.
Novozymes A/S Company Profile
Novozymes A/S is a Danish biotechnology company that develops, produces and markets industrial enzymes and microorganisms. Headquartered in Bagsværd, Denmark, the company focuses on using biological solutions to improve industrial processes across a range of end markets. Its offerings are designed to increase product performance or process efficiency while reducing energy, water and chemical consumption for customers.
The company’s product portfolio includes enzymes and microbial solutions for household care (detergents and cleaning products), food and beverages (baking, brewing and dairy applications), bioenergy (enzymes for biofuel production), agriculture (microbial crop inputs and biocontrols) and industrial processing (textiles, pulp and paper, and wastewater treatment).
Read More
- Five stocks we like better than Novozymes A/S
- Blink Charging: 3,648%. NIO: 1,755%. None of them are Tesla.
- The gold chart Wall Street is terrified of…
- Why this rare resource setup is catching early attention
- Buy this Gold Stock Before May 15th, 2026
- J.P. Morgan is betting on this coin
Receive News & Ratings for Novozymes A/S Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Novozymes A/S and related companies with MarketBeat.com's FREE daily email newsletter.
